Stephen Hammack, MD
Family Medicine · Flowood, MSNPI 1639396393
Payments from drug & device makers
Across 528 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$1K
- Novo Nordisk$913
- Lilly USA, LLC$597
- GSK$572
- Amgen$352
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,66899%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 95 | $1,429 |
| AbbVie(2 entities) | 100 | $1,293 |
| Novo Nordisk | 73 | $913 |
| Lilly USA, LLC | 46 | $597 |
| GSK | 50 | $572 |
| Amgen | 23 | $352 |
| Abbott | 15 | $298 |
| AstraZeneca | 18 | $272 |
| Johnson & Johnson | 15 | $246 |
| Boehringer Ingelheim | 14 | $240 |
| Novartis | 16 | $185 |
| Inspire Medical Systems, Inc. | 3 | $170 |
| Lundbeck LLC | 3 | $141 |
| Merck | 6 | $117 |
| Astellas Pharma US Inc | 6 | $93 |
| Sanofi Pasteur Inc. | 4 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| Currax Pharmaceuticals LLC | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Supernus Pharmaceuticals, Inc. | 4 | $57 |
| Bayer | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Exact Sciences | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Inari Medical, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Boston Scientific | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,718 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $76,651 |
| OzempicSemaglutide | 48 | $52,632 |
| EliquisApixaban | 57 | $45,899 |
| JardianceEmpagliflozin | 62 | $45,477 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $26,480 |
| TrulicityDulaglutide | 25 | $23,470 |
| JanuviaSitagliptin Phosphate | 26 | $20,468 |
| LinzessLinaclotide | 31 | $18,055 |
| VraylarCariprazine Hcl | 11 | $15,281 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $15,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,077 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 33 | $7,559 |
| Bydureon BciseExenatide Microspheres | 11 | $7,223 |
| TradjentaLinagliptin | 11 | $5,291 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 132 | $2,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $597 | $100,12194 claims |
| Novo NordiskOzempic | $913 | $52,63248 claims |
| Boehringer IngelheimJardiance, Tradjenta | $240 | $50,76873 claims |
| PfizerEliquis | $1,429 | $45,89957 claims |
| AbbVieLinzess, Vraylar, Synthroid | $1,293 | $34,49663 claims |
| GSKTrelegy Ellipta, Shingrix | $572 | $20,63650 claims |
| MerckJanuvia | $117 | $20,46826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Flowood
- Todd PerkinsFlowood$22K
- John MaddenFlowood$20K
- Rebekah MoulderFlowood$16K
- Landall HathornFlowood$11K
- Cynthia AllenFlowood$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.